About +
- Our Story
- Meet the Team
Inhaled Interferon β +
- Our Programmes
- Publications
Investors +
News +
- Press Releases & Media
- TR-1/Options Press Releases
Careers
Contact

About
Inhaled Interferon β
Investors
News
Careers
Contact

Our Story
Meet the Team

Our Programmes
Publications

Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance

Press Releases & Media
TR-1/Options Press Releases

Investors

Investor News

Subscribe to news

Result of AGM30th June 2022
Posting of Annual Report and Notice of AGM6th June 2022
Full Year Results25th May 2022
Synairgen presents at ATS 202216th May 2022
Presentation at ECCMID25th April 2022
Synairgen to present at ATS 20225th April 2022
Synairgen provides update on ACTIV-2 Trial17th March 2022
Update on SNG0013rd March 2022
Topline results from Phase 3 SPRINTER trial21st February 2022
Synairgen announces partnership with Ashfield Engage6th January 2022

Interferon Beta
Our Science
COVID-19
COPD
Asthma
Relevant Publications

About
Our Story
Team
Careers
Contact

Investors
Investors Overview
Performance
Reports & Presentations
Investor News
Analysts

Media
News
Resources

Cookie Policy Legal Privacy Policy

© Synairgen plc. All Rights ReservedRegistered in England and Wales No. 5233429 | Site by Ether